Article PDF
Avoid common mistakes on your manuscript.
Literatur
Ehrlich HJ, Müller M, Oh H, Tambyah P, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Kistner O, Barrett PN (2008) A clinical trial of a whole virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573–2584
Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, Vartian N, Bobrovsky R, Kistner O, Barrett PN (2009) An open label phase II study to assess the immunogenicity and safety of a booster vaccination with a heterologous vero cell derived whole virus H5N1 influenza vaccine. J Inf Dis 200 (7): 1113–1118
ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361 (20): 1925–1934 (Epub 2009 Oct 8)
Angell M (2005) The truth about the drug companies: how they deceive us and what to do about it. ISBN-10: 0375760946. Random House Trade Paperbacks (2005)
Clark J (2005) Five futures for academic medicine: the ICRAM scenarios. BMJ 331 (7508): 101–104
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müller, M. Zur Medienberichterstattung über den in Österreich verfügbaren Impfstoff gegen pandemische Influenza A/H1N1. Wien Klin Wochenschr 121, 663–664 (2009). https://doi.org/10.1007/s00508-009-1277-5
Issue Date:
DOI: https://doi.org/10.1007/s00508-009-1277-5